Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.70 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.70 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.52 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.52 |
| ▸ | ITK | Q08881 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | DAO | P14920 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | DDO | Q99489 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6333156 | 0.92 | KDR (0.70) | KDRCHEK1CASP3SENP8SENP7 | |
| SCHEMBL5082009 | 0.88 | KDR (0.68) | KDRCHEK1 | |
| SCHEMBL29370693 | 0.84 | KDR (1.00) | KDRCHEK1DAOKDM4EMAPT | |
| SCHEMBL5076094 | 0.84 | KDR (1.00) | KDRCHEK1DAOKDM4EMAPT | |
| SCHEMBL27488931 | 0.82 | KDR (0.77) | KDRCHEK1DAODDO | |
| SCHEMBL29206332 | 0.80 | KDR (0.55) | KDRCHEK1CASP3SENP8SENP7 | |
| SCHEMBL27489248 | 0.80 | KDR (0.79) | KDRCHEK1DAOKDM4EMAPT | |
| SCHEMBL14559496 | 0.80 | KDR (0.62) | KDRCHEK1PARP1KDM4EHSD17B10 | |
| SCHEMBL5076073 | 0.80 | KDR (1.00) | KDRCHEK1PARP1 | |
| SCHEMBL5551798 | 0.80 | KDR (0.62) | KDRCHEK1PARP1KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080274107-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2008-11-06 | — | — | US | disclosed |
| US-7186723-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| CN-1213045-C | Tyrosine kinase inhibitors | MERCK & CO INC (US) | 2005-08-03 | — | — | CN | disclosed |
| US-20050096344-A1 | Tyrosine kinase inhibitors | FRALEY MARK E (US) | 2005-05-05 | — | — | US | disclosed |
| EP-1226136-B1 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20040235826-A1 | Tyrosine kinase ihnibitors | MERCK SHARP & DOHME CORP. | 2004-11-25 | — | — | US | disclosed |
| US-6794393-B1 | inhibitors of VEGF; angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases; 1H-indole compounds having a fused nitrogen heterocycle amide in the 2-position | MERCK & CO., INC. | 2004-09-21 | — | — | US | disclosed |
| CN-1409708-A | Tyrosine kinase inhibitors | MERCK & CO INC (US) | 2003-04-09 | — | — | CN | disclosed |
| WO-2003020699-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-03-13 | — | — | WO | disclosed |
| EP-1226136-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2002-07-31 | — | — | EP | disclosed |
| US-6306874-B1 | ENZYME INHIBITORS SUCH AS ANGIOGENESIS, CANCER, TUMOR GROWTH, ATHEROSCLEROSIS, AGE RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY, INFLAMMATORY DISEASES, AND THE LIKE IN MAMMALS. | MERCK & CO., INC. | 2001-10-23 | — | — | US | disclosed |
| WO-2001029025-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235826-A1 | Tyrosine kinase ihnibitors | KDR, FLT4, ERBB2 | KDR 1/4885CHEK1 955/4885CASP3 979/4885 |
| US-20050096344-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885CHEK1 499/4885CASP3 971/4885 |
| US-20080274107-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885CHEK1 499/4885CASP3 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.